Five Arrows Principal Investments-backed Sygnature Discovery completed the acquisition of NuChem Sciences.

Five Arrows Principal Investments-backed Sygnature Discovery, UK based integrated drug discovery contract research organization, completed the acquisition of NuChem Sciences, a Canadian drug discovery in chemistry contract research organization. Financial details were not disclosed. "This acquisition represents a pivotal milestone in the Sygnature growth plan, allowing us to deliver better discovery solutions to customers around the world. The addition of NuChem Sciences greatly enhances Sygnature Discovery’s offering, making us a highly differentiated and integrated drug discovery partner with unrivalled scale and range. NuChem is a like-minded business that complements Sygnature’s existing services, towards our joint mission of improving the world’s health,” Dr Simon Hirst, Sygnature Discovery CEO.